Table 1.

Clinical characteristics and laboratory findings of 153 amyloid-positive patients. Baseline data were at diagnosis of amyloidosis for biologic group and at initial administration of biologics for nonbiologic group. Data are mean (SD) unless otherwise indicated.

CharacteristicsNo. Patient with Amyloidosis
Biologic Group, n (%)Nonbiologic Group, n (%)p
Sex, male/female7/462/780.03
Mean onset age of RA, years (SD), range46.9 (13.6), 10–70.545.4 (11.1), 20–650.6
Mean age of diagnosis of amyloidosis, yrs (SD), range63.2 (9.6), 31–7260.9 (9.7), 28–790.191
Duration of RA prior to diagnosis of amyloidosis, years (SD), range16.8 (9.8), 1–4215.5 (9.0), 2–530.4
Stage, n (%)0.236
  II4 (7.5)2 (2.5)
  III11 (20.8)12 (15.0)
  IV38 (71.7)66 (82.5)
Class, n (%)0.472
  225 (47.2)46 (56.2)
  324 (45.3)28 (36.3)
  44 (7.5)6 (7.5)
MTX therapy (yes/mo)21/3227/530.58
Total protein, g/dl6.6 (1.2)6.6 (0.9)0.885
Serum albumin, g/dl3.3 (0.7)3.4 (0.7)0.298
γ globulin, %22.5 (7.7)22.1 (6.5)0.1
BUN, mg/dl22.0 (10.5)29.4 (21.6)0.055
Cr, mg/dl0.9 (0.5)1.5 (1.3)0.012
CRP, mg/dl2.1 (2.0)4.7 (3.7)0.000
ESR Westergren, mm/h52.0 (33.5)80.8 (39.8)0.224
RF, IU/ml167.4 (264.7)129.7 (209.9)0.795
Hemoglobin, g/dl11.2 (1.8)10.4 (2.0)0.06
Hematocrit, %34.9 (5.2)32.5 (5.9)0.057
Creatinine clearance, ml/min/1.73 m276.9 (33.5)50.9 (35.7)0.0004
24-hour urinary protein, g/24 h0.8 (0.9)1.4 (1.8)0.12
  • BUN: blood urea nitrogen; Cr: serum creatinine; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; MTX: methotrexate; RA: rheumatoid arthritis.